Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Brefeldin A (BFA) (HB2949)
Description:Reversible protein transport inhibitor. Commonly used in cytokine staining. Enhances CRISPR-mediated HDR.
Purity:>98%
Calyculin A (HB0161)
Description:Potent, selective protein phosphatase 1 / 2A inhibitor
Purity:>98%
Cyclosporin A (HB0220)
Description:Potent calcineurin inhibitor. Inhibits MPTP opening.
Purity:>99%
Monensin sodium salt (HB4882)
Description:Protein transport inhibitor. Commonly used in cytokine staining.
Purity:>98%
Nocodazole (HB3999)
Description:Mitosis inhibitor, widely used as a cell cycle synchronizing agent. Enhances HDR efficiency and increases Cas9-mediated gene editing frequencies.
Purity:>98%
- Description:
Phosphatase Inhibitor Cocktail solution (with Calyculin A) for the inhibition of serine/threonine and alkaline phosphatases.
- Description:
Protease & Phosphatase Inhibitor Cocktail solution (EDTA free)
- Description:
Protease & Phosphatase Inhibitor Cocktail solution (plus EDTA)
- Description:
Protease Inhibitor Cocktail powder for general use to inhibit a broad range of proteases and esterases
- Description:
Protease Inhibitor Cocktail (EDTA free) solution for plant cell and tissue extract use